KR100713607B1 - 5-ｈｔ1ａ 수용체 서브타입 작용물질 - Google Patents
5-ｈｔ1ａ 수용체 서브타입 작용물질 Download PDFInfo
- Publication number
- KR100713607B1 KR100713607B1 KR1020067014046A KR20067014046A KR100713607B1 KR 100713607 B1 KR100713607 B1 KR 100713607B1 KR 1020067014046 A KR1020067014046 A KR 1020067014046A KR 20067014046 A KR20067014046 A KR 20067014046A KR 100713607 B1 KR100713607 B1 KR 100713607B1
- Authority
- KR
- South Korea
- Prior art keywords
- schizophrenia
- disorder
- haloperidol
- drug
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000556 agonist Substances 0.000 title description 10
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 title 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 title 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 106
- 239000003814 drug Substances 0.000 claims abstract description 38
- 229940079593 drug Drugs 0.000 claims abstract description 37
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 208000035475 disorder Diseases 0.000 claims abstract description 18
- 125000005606 carbostyryl group Chemical group 0.000 claims abstract description 15
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims abstract description 3
- 239000012453 solvate Substances 0.000 claims abstract 2
- 201000000980 schizophrenia Diseases 0.000 claims description 68
- 208000031555 Treatment-Resistant Schizophrenia Diseases 0.000 claims description 46
- 208000010877 cognitive disease Diseases 0.000 claims description 46
- 208000028698 Cognitive impairment Diseases 0.000 claims description 39
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 32
- 239000000164 antipsychotic agent Substances 0.000 claims description 17
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical group C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 16
- 229960003878 haloperidol Drugs 0.000 claims description 16
- -1 carbostyryl compound Chemical class 0.000 claims description 14
- 229960001534 risperidone Drugs 0.000 claims description 14
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 14
- 208000029252 treatment-refractory schizophrenia Diseases 0.000 claims description 14
- 229960005017 olanzapine Drugs 0.000 claims description 13
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 13
- 230000000399 orthopedic effect Effects 0.000 claims description 13
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 229960001076 chlorpromazine Drugs 0.000 claims description 10
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 7
- 229960000762 perphenazine Drugs 0.000 claims description 7
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims description 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 3
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 3
- 229960003634 pimozide Drugs 0.000 claims description 3
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 abstract description 40
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 2
- 108020003175 receptors Proteins 0.000 description 32
- 102000005962 receptors Human genes 0.000 description 32
- 230000000694 effects Effects 0.000 description 30
- 238000012360 testing method Methods 0.000 description 26
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 19
- 229960004170 clozapine Drugs 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 230000027455 binding Effects 0.000 description 14
- 239000000018 receptor agonist Substances 0.000 description 14
- 229940044601 receptor agonist Drugs 0.000 description 14
- 239000004031 partial agonist Substances 0.000 description 13
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 12
- 208000024827 Alzheimer disease Diseases 0.000 description 10
- 239000012528 membrane Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- XIGAHNVCEFUYOV-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-n-pyridin-2-ylcyclohexanecarboxamide Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC=CC=C1N1CCN(CCN(C(=O)C2CCCCC2)C=2N=CC=CC=2)CC1 XIGAHNVCEFUYOV-BTJKTKAUSA-N 0.000 description 8
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 8
- 229940127236 atypical antipsychotics Drugs 0.000 description 8
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 8
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 7
- 208000018737 Parkinson disease Diseases 0.000 description 7
- 229960004372 aripiprazole Drugs 0.000 description 7
- 208000020401 Depressive disease Diseases 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 208000024714 major depressive disease Diseases 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000000561 anti-psychotic effect Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000001050 pharmacotherapy Methods 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 239000003723 serotonin 1A agonist Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010026749 Mania Diseases 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 230000000698 schizophrenic effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 208000027776 Extrapyramidal disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010021030 Hypomania Diseases 0.000 description 2
- 208000019430 Motor disease Diseases 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 201000003104 endogenous depression Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RCRBVJFAYTWJOK-UHFFFAOYSA-N 2-(dipropylamino)-1,2,3,4-tetrahydronaphthalen-1-ol Chemical compound C1=CC=C2C(O)C(N(CCC)CCC)CCC2=C1 RCRBVJFAYTWJOK-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000025748 atypical depressive disease Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229940068796 clozaril Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003727 serotonin 1A antagonist Substances 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77021001A | 2001-01-29 | 2001-01-29 | |
| US09/770,210 | 2001-01-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057019896A Division KR100653591B1 (ko) | 2001-01-29 | 2002-01-29 | 5-ｈｔ1ａ 수용체 서브타입 작용물질 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20060085260A KR20060085260A (ko) | 2006-07-26 |
| KR100713607B1 true KR100713607B1 (ko) | 2007-05-02 |
Family
ID=25087808
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067014046A Expired - Lifetime KR100713607B1 (ko) | 2001-01-29 | 2002-01-29 | 5-ｈｔ1ａ 수용체 서브타입 작용물질 |
| KR1020067005164A Ceased KR100763288B1 (ko) | 2001-01-29 | 2002-01-29 | 5-ｈｔ1ａ 수용체 서브타입 작용물질 |
| KR1020077010561A Expired - Lifetime KR100825705B1 (ko) | 2001-01-29 | 2002-01-29 | 5-ｈｔ1ａ 수용체 서브타입 작용물질 |
| KR1020037008565A Expired - Lifetime KR100601073B1 (ko) | 2001-01-29 | 2002-01-29 | 5-ｈｔ1ａ 수용체 서브타입 작용물질 |
| KR1020057019896A Expired - Lifetime KR100653591B1 (ko) | 2001-01-29 | 2002-01-29 | 5-ｈｔ1ａ 수용체 서브타입 작용물질 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067005164A Ceased KR100763288B1 (ko) | 2001-01-29 | 2002-01-29 | 5-ｈｔ1ａ 수용체 서브타입 작용물질 |
| KR1020077010561A Expired - Lifetime KR100825705B1 (ko) | 2001-01-29 | 2002-01-29 | 5-ｈｔ1ａ 수용체 서브타입 작용물질 |
| KR1020037008565A Expired - Lifetime KR100601073B1 (ko) | 2001-01-29 | 2002-01-29 | 5-ｈｔ1ａ 수용체 서브타입 작용물질 |
| KR1020057019896A Expired - Lifetime KR100653591B1 (ko) | 2001-01-29 | 2002-01-29 | 5-ｈｔ1ａ 수용체 서브타입 작용물질 |
Country Status (19)
| Country | Link |
|---|---|
| EP (3) | EP1712225B1 (https=) |
| JP (4) | JP4178032B2 (https=) |
| KR (5) | KR100713607B1 (https=) |
| CN (3) | CN1239154C (https=) |
| AR (4) | AR032641A1 (https=) |
| AT (3) | ATE504293T1 (https=) |
| AU (4) | AU2002226752C1 (https=) |
| BR (1) | BR0206237A (https=) |
| CA (2) | CA2429496C (https=) |
| CY (3) | CY1105631T1 (https=) |
| DE (3) | DE60220325T2 (https=) |
| DK (3) | DK1712225T3 (https=) |
| ES (3) | ES2261652T3 (https=) |
| MX (2) | MXPA03006603A (https=) |
| MY (1) | MY129355A (https=) |
| PH (1) | PH12014500937A1 (https=) |
| PT (3) | PT1712225E (https=) |
| TW (2) | TWI331919B (https=) |
| WO (1) | WO2002060423A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US8703772B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| DE10148233A1 (de) * | 2001-09-28 | 2003-04-10 | Boehringer Ingelheim Pharma | Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme |
| CA2529857A1 (en) * | 2002-07-30 | 2004-02-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| KR100842694B1 (ko) * | 2002-12-27 | 2008-07-01 | 오쓰까 세이야꾸 가부시키가이샤 | 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제 |
| AR042806A1 (es) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
| GEP20084567B (en) * | 2003-05-23 | 2008-12-25 | Otsuka Pharma Co Ltd | Carbostyril derivatives and mood stabilizers for treating mood disorders |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| FR2865650B1 (fr) * | 2004-01-30 | 2008-06-13 | Biocortech | Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil |
| WO2006090273A2 (en) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia |
| JP2009503020A (ja) * | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症の治療におけるフリバンセリンの使用 |
| TW200848041A (en) | 2007-03-30 | 2008-12-16 | Otsuka Pharma Co Ltd | A medicament for treating schizophrenia comprising cilostazol |
| GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| JP2009286740A (ja) * | 2008-05-30 | 2009-12-10 | Otsuka Pharmaceut Co Ltd | アリピプラゾールを含有する逆耐性抑制剤 |
| EP2338873A1 (en) | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
| TW201343201A (zh) | 2012-03-06 | 2013-11-01 | Otsuka Pharma Co Ltd | 持續釋放型口服固體製劑 |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4764416A (en) | 1986-07-01 | 1988-08-16 | Mitsubishi Denki Kabushiki Kaisha | Electric element circuit using oxidation-reduction substances |
| EP0367141A2 (en) * | 1988-10-31 | 1990-05-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| WO1998008817A1 (en) * | 1996-08-27 | 1998-03-05 | American Home Products Corporation | 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54130587A (en) * | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| JPS5646812A (en) * | 1979-09-27 | 1981-04-28 | Otsuka Pharmaceut Co Ltd | Central nervous system depressant |
| JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
| JP3155276B2 (ja) * | 1991-05-20 | 2001-04-09 | ファルマシア・アンド・アップジョン・カンパニー | カルボキサミド−（１，２ｎ）−カルボサイクリック−２−アミノテトラリン誘導体 |
| US5532240A (en) * | 1991-12-26 | 1996-07-02 | Yoshitomi Pharmaceutical Industries, Ltd. | Condensed thiophene compound and pharmaceutical use thereof |
| WO1994009765A1 (en) * | 1992-10-23 | 1994-05-11 | New York University | Functional interactions between glial s-100b and central nervous system serotonergic neurons |
| DK148292D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Forbindelser |
| JP2959615B2 (ja) * | 1993-06-24 | 1999-10-06 | 吉富製薬株式会社 | 縮合型チオフェン化合物およびその医薬用途 |
| JPH09291034A (ja) * | 1996-02-27 | 1997-11-11 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピリジン化合物およびその医薬としての用途 |
| US5688950A (en) * | 1996-04-23 | 1997-11-18 | Neurogen Corporation | Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands |
| DK0904273T3 (da) * | 1996-05-07 | 2003-07-07 | Pfizer | Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist |
| JP4012994B2 (ja) * | 1996-05-08 | 2007-11-28 | 大塚製薬株式会社 | 抗不安薬 |
| CN1289333A (zh) * | 1998-02-03 | 2001-03-28 | 美国家用产品公司 | 用作血清素－1a受体激动剂的噁唑衍生物 |
| ZA992670B (en) * | 1998-04-13 | 2000-10-12 | American Home Prod | 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists. |
| JPH11335286A (ja) * | 1998-05-25 | 1999-12-07 | Mitsui Chem Inc | ドーパミン拮抗薬の効果増強剤 |
| AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| EP1397145B1 (en) * | 2001-06-19 | 2006-09-06 | Norbert Müller | Use of cox-2 inhibitors for the treatment of schizophrenia, or tic disorders |
| AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
-
2002
- 2002-01-15 AR ARP020100118A patent/AR032641A1/es not_active Application Discontinuation
- 2002-01-25 TW TW093127321A patent/TWI331919B/zh not_active IP Right Cessation
- 2002-01-25 TW TW091101289A patent/TWI302832B/zh not_active IP Right Cessation
- 2002-01-26 MY MYPI20020297A patent/MY129355A/en unknown
- 2002-01-29 AT AT06015782T patent/ATE504293T1/de active
- 2002-01-29 ES ES02716434T patent/ES2261652T3/es not_active Expired - Lifetime
- 2002-01-29 KR KR1020067014046A patent/KR100713607B1/ko not_active Expired - Lifetime
- 2002-01-29 MX MXPA03006603A patent/MXPA03006603A/es active IP Right Grant
- 2002-01-29 AT AT05023971T patent/ATE362763T1/de active
- 2002-01-29 AT AT02716434T patent/ATE322894T1/de active
- 2002-01-29 KR KR1020067005164A patent/KR100763288B1/ko not_active Ceased
- 2002-01-29 DE DE60220325T patent/DE60220325T2/de not_active Expired - Lifetime
- 2002-01-29 EP EP06015782A patent/EP1712225B1/en not_active Revoked
- 2002-01-29 EP EP02716434A patent/EP1355639B1/en not_active Expired - Lifetime
- 2002-01-29 MX MX2011010975A patent/MX344556B/es unknown
- 2002-01-29 JP JP2002560616A patent/JP4178032B2/ja not_active Expired - Lifetime
- 2002-01-29 ES ES05023971T patent/ES2286755T3/es not_active Expired - Lifetime
- 2002-01-29 WO PCT/JP2002/000626 patent/WO2002060423A2/en not_active Ceased
- 2002-01-29 EP EP05023971A patent/EP1621198B1/en not_active Revoked
- 2002-01-29 AU AU2002226752A patent/AU2002226752C1/en not_active Expired
- 2002-01-29 CA CA2429496A patent/CA2429496C/en not_active Expired - Lifetime
- 2002-01-29 CN CNB028035518A patent/CN1239154C/zh not_active Expired - Lifetime
- 2002-01-29 CA CA2700314A patent/CA2700314C/en not_active Expired - Lifetime
- 2002-01-29 CN CNA2006100943881A patent/CN1879624A/zh active Pending
- 2002-01-29 ES ES06015782T patent/ES2363366T3/es not_active Expired - Lifetime
- 2002-01-29 DK DK06015782.3T patent/DK1712225T3/da active
- 2002-01-29 DK DK05023971T patent/DK1621198T3/da active
- 2002-01-29 KR KR1020077010561A patent/KR100825705B1/ko not_active Expired - Lifetime
- 2002-01-29 DE DE60210581T patent/DE60210581T2/de not_active Expired - Lifetime
- 2002-01-29 PT PT06015782T patent/PT1712225E/pt unknown
- 2002-01-29 PT PT05023971T patent/PT1621198E/pt unknown
- 2002-01-29 DK DK02716434T patent/DK1355639T3/da active
- 2002-01-29 PT PT02716434T patent/PT1355639E/pt unknown
- 2002-01-29 BR BR0206237-2A patent/BR0206237A/pt not_active Application Discontinuation
- 2002-01-29 KR KR1020037008565A patent/KR100601073B1/ko not_active Expired - Lifetime
- 2002-01-29 KR KR1020057019896A patent/KR100653591B1/ko not_active Expired - Lifetime
- 2002-01-29 CN CNB2005100228288A patent/CN100450485C/zh not_active Expired - Lifetime
- 2002-01-29 DE DE60239711T patent/DE60239711D1/de not_active Expired - Lifetime
-
2005
- 2005-04-27 AU AU2005201772A patent/AU2005201772C1/en not_active Expired
-
2006
- 2006-06-28 CY CY20061100884T patent/CY1105631T1/el unknown
-
2007
- 2007-04-17 AU AU2007201701A patent/AU2007201701B2/en not_active Expired
- 2007-07-09 JP JP2007179275A patent/JP4896831B2/ja not_active Expired - Lifetime
- 2007-08-20 CY CY20071101093T patent/CY1108031T1/el unknown
-
2009
- 2009-10-29 AU AU2009233591A patent/AU2009233591B2/en not_active Expired
-
2010
- 2010-12-28 AR ARP100104973A patent/AR079761A2/es not_active Application Discontinuation
-
2011
- 2011-04-08 AR ARP110101189A patent/AR080849A2/es not_active Application Discontinuation
- 2011-04-18 CY CY20111100391T patent/CY1111392T1/el unknown
- 2011-06-15 JP JP2011133033A patent/JP2011184460A/ja active Pending
- 2011-06-15 JP JP2011133032A patent/JP5683010B2/ja not_active Expired - Lifetime
-
2014
- 2014-04-28 PH PH12014500937A patent/PH12014500937A1/en unknown
-
2015
- 2015-03-13 AR ARP150100766A patent/AR099754A2/es not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4764416A (en) | 1986-07-01 | 1988-08-16 | Mitsubishi Denki Kabushiki Kaisha | Electric element circuit using oxidation-reduction substances |
| EP0367141A2 (en) * | 1988-10-31 | 1990-05-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| WO1998008817A1 (en) * | 1996-08-27 | 1998-03-05 | American Home Products Corporation | 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8426423B2 (en) | Method of treating Attention Deficit Hyper-Activity Disorder | |
| JP5683010B2 (ja) | ５−ｈｔ１ａ受容体サブタイプ作動薬 | |
| AU2002226752A1 (en) | Substituted carbostyril derivatives as 5-HT1A receptor subtype agonists | |
| AU2013203248A1 (en) | Substituted carbostyril derivatives as 5-HT 1A receptor subtype agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20060712 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060908 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20070221 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20070425 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20070425 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20100414 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110318 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120418 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130404 Start annual number: 7 End annual number: 7 |
|
| J206 | Request for trial to confirm the scope of a patent right | ||
| PJ0206 | Trial to confirm the scope of a patent |
Patent event code: PJ02062R01D Patent event date: 20130613 Comment text: Request for Trial Patent event code: PJ02061E01I Patent event date: 20070425 Comment text: Registration of Establishment Decision date: 20130830 Request date: 20130613 Appeal identifier: 2013100001575 Appeal kind category: Confirmation of the scope of right_affirmative |
|
| J206 | Request for trial to confirm the scope of a patent right | ||
| PJ0206 | Trial to confirm the scope of a patent |
Decision date: 20131022 Request date: 20130731 Appeal identifier: 2013100002041 Appeal kind category: Confirmation of the scope of right_affirmative Decision date: 20130927 Request date: 20130731 Appeal identifier: 2013100002040 Appeal kind category: Confirmation of the scope of right_affirmative Patent event code: PJ02062R01D Patent event date: 20130731 Comment text: Request for Trial Patent event code: PJ02061E01I Patent event date: 20070425 Comment text: Registration of Establishment Decision date: 20130925 Request date: 20130731 Appeal identifier: 2013100002039 Appeal kind category: Confirmation of the scope of right_affirmative |
|
| J121 | Written withdrawal of request for trial | ||
| PJ1201 | Withdrawal of trial |
Patent event code: PJ12011R01D Patent event date: 20130830 Comment text: Written Withdrawal of Request for Trial Appeal identifier: 2013100001575 Request date: 20130613 Appeal kind category: Confirmation of the scope of right_affirmative Decision date: 20130830 |
|
| J121 | Written withdrawal of request for trial | ||
| PJ1201 | Withdrawal of trial |
Patent event code: PJ12011R01D Patent event date: 20130925 Comment text: Written Withdrawal of Request for Trial Appeal identifier: 2013100002039 Request date: 20130731 Appeal kind category: Confirmation of the scope of right_affirmative Decision date: 20130925 |
|
| J121 | Written withdrawal of request for trial | ||
| PJ1201 | Withdrawal of trial |
Patent event code: PJ12011R01D Patent event date: 20130927 Comment text: Written Withdrawal of Request for Trial Appeal identifier: 2013100002040 Request date: 20130731 Appeal kind category: Confirmation of the scope of right_affirmative Decision date: 20130927 |
|
| J121 | Written withdrawal of request for trial | ||
| PJ1201 | Withdrawal of trial |
Patent event code: PJ12011R01D Patent event date: 20131022 Comment text: Written Withdrawal of Request for Trial Appeal identifier: 2013100002041 Request date: 20130731 Appeal kind category: Confirmation of the scope of right_affirmative Decision date: 20131022 |
|
| FPAY | Annual fee payment |
Payment date: 20140401 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140401 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20170330 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170330 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20180328 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180328 Start annual number: 12 End annual number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20190328 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190328 Start annual number: 13 End annual number: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210329 Start annual number: 15 End annual number: 15 |
|
| PC1801 | Expiration of term |
Termination date: 20220729 Termination category: Expiration of duration |